West Pharmaceutical Services (WST) Stock Price, Quote & News

Company Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applicati...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 610 594 2900

Website: www.westpharma.com

Address:

530 Herman O. West Drive, Exton, United States

Estimize Feb. 23 at 12:00 PM

Wall St is expecting 1.68 EPS for $WST Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_cont

0 · Reply

FadeLars Feb. 20 at 4:33 PM

$WST West Pharmaceutical supplies packaging for injectable drugs. Demand is stable and high margin. Growth tracks biologics adoption.

0 · Reply

deankell Feb. 18 at 1:37 AM

$WST West Pharmaceutical (WST) declares $0.22/share quarterly dividend, in line with previous. Forward yield 0.36% Payable May 6; for shareholders of record April 29; ex-div April 29.

0 · Reply

deankell Feb. 18 at 1:28 AM

$WST 17 Feb 2026 05:19:12 PM | Seeking Alpha West Pharmaceutical Services (WST) said its board has authorized an up to $1B share repurchase program. The company exhausted a prior buyback that had an expiration date of Dec. 31.

0 · Reply

d_risk Feb. 17 at 10:04 PM

$WST - West Pharmaceutical Services Inc - 10K - Updated Risk Factors WST’s 2026 10-K sharpens macro and operational risk: deeper focus on recession and market volatility, tariffs and banking fragility, capacity and supply-chain fragility (single-source and climate/pandemic disruptions), new credit and customer concentration risks, added product liability and GLP-1 displacement threats, climate and PFAS exposure, tighter anti-bribery and reimbursement headwinds, deal and Daikyo licensing execution risk, talent and innovation dependence, dividends not assured, and a new warning on internal controls and potential stock hit. #PharmaceuticalManufacturing #MarketVolatility #SupplyChainRisk #RegulatoryCompliance #ClimateExposure 🟢 Added 🟠 Removed https://d-risk.ai/WST/10-K/2026-02-17

0 · Reply

ZacksResearch Feb. 12 at 7:04 PM

$WST delivers the double beat — and the market’s paying attention. 📈 Q4 EPS and revenue topped estimates, driven by proprietary products, and shares jumped nearly 3.6% premarket on an upbeat 2026 outlook. Add in plans for a SmartDose sale by mid-2026, and there’s a clear strategic shift underway. Is this the start of a stronger rerating? Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2863521/wsts-q4-earnings-sales-beat-smartdose-sale-by-mid-2026-stock-up?cid=sm-stocktwits-2-2863521-teaser-33447&ADID=SYND_STOCKTWITS_TWEET_2_2863521_TEASER_33447

0 · Reply

ZacksResearch Feb. 12 at 6:04 PM

$WST posts solid Q4 earnings beat, but what's next for 2026? 📈 West Pharmaceutical delivered a 12.1% YoY adjusted EPS rise, beating estimates by 11.5%, with robust Proprietary Products driving growth. However, shares have gained only 2.6% in the past six months compared to the industry's 21.8% rally. Discover what could drive WST higher in 2026 👉 https://www.zacks.com/stock/news/2863521/wsts-q4-earnings-sales-beat-smartdose-sale-by-mid-2026-stock-up?cid=sm-stocktwits-2-2863521-body-33427&ADID=SYND_STOCKTWITS_TWEET_2_2863521_BODY_33427

0 · Reply

Tokenist Feb. 12 at 1:32 PM

📊 Earnings check-in: $IRM $USFD $WST all dropped Q4 numbers, and overall, it was a solid showing. 🗄️ $IRM posted record results, EPS beat, and double-digit growth fueled by data centers + digital services. 2026 guide calls for 10–13% revenue growth. Quiet compounder vibes. 🍽️ $USFD grew sales 3%+ and nearly doubled net income YoY. EBITDA up 11%. 2026 outlook: mid-single-digit sales growth, double-digit EPS growth. Execution story still intact. 💉 $WST beat on both revenue and EPS, driven by strong demand in high-value injectable components. 2026 guide points to steady 5–7% organic growth. Not flashy names — but steady operators putting up numbers in a shaky tape.

1 · Reply

StocktwitsEarnings Feb. 12 at 12:27 PM

$WST Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.83 up 2.23% YoY • Reported revenue of $805M up 7.51% YoY • Full-year 2026 net sales for West Pharmaceutical Services are expected to be in a range of $3.22B to $3.28B, while adjusted-diluted EPS is projected between $7.85 and $8.20.

0 · Reply

ZacksResearch Feb. 11 at 7:28 PM

Big earnings week for $BAX, $WST, and $DXCM — which stock should be on your radar? 📈 🔍 $BAX faces operational headwinds with a projected 8.6% EPS decline, despite a slight revenue uptick. 💉 $WST’s high-value product demand could boost margins, with EPS expected to rise 0.6%. 📊 $DXCM shows potential for a 44.4% EPS jump — thanks to a rebound in U.S. new customer starts as G7 deployment issues eased. Discover which medtech stock could outperform here 👉 https://www.zacks.com/stock/news/2854637/medical-device-stocks-to-report-earnings-on-feb-12-bax-wst-dxcm?cid=sm-stocktwits-2-2854637-body-33202&ADID=SYND_STOCKTWITS_TWEET_2_2854637_BODY_33202

0 · Reply

West Announces Quarterly Dividend and Share Repurchase Program

Feb 12, 2026, 2:14 PM EST - 10 days ago

West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 6:58 AM EST - 11 days ago

West Pharma forecasts 2026 profit above estimates on strong demand for drug components

Feb 12, 2026, 6:00 AM EST - 11 days ago

West Reports Fourth-Quarter and Full-Year 2025 Results

Feb 5, 2026, 3:24 PM EST - 17 days ago

West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript

Jan 29, 2026, 6:00 AM EST - 25 days ago

West to Host Fourth-Quarter and Full-Year 2025 Conference Call

Jan 26, 2026, 10:00 AM EST - 4 weeks ago

Time To Buy The Dip In West Pharmaceutical Stock?

Jan 25, 2026, 10:09 AM EST - 4 weeks ago

Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards

BSY CSGP GNRC IDXX JKHY POOL RGEN

Jan 20, 2026, 6:00 AM EST - 4 weeks ago

West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

Jan 14, 2026, 3:45 PM EST - 5 weeks ago

West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:00 AM EST - 6 weeks ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

ABBV

Jan 12, 2026, 6:00 AM EST - 6 weeks ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

ABBV

Dec 31, 2025, 8:47 AM EST - 7 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 12, 2025, 6:00 AM EST - 2 months ago

West to Participate in Upcoming Investor Conference

Dec 10, 2025, 6:00 AM EST - 2 months ago

West Declares Quarterly Dividend

Dec 8, 2025, 9:03 PM EST - 2 months ago

Top 50 High-Quality Dividend Growth Stocks For December 2025

ACN ALLE APH DHI DPZ FDS GGG

Dec 2, 2025, 5:13 PM EST - 2 months ago

West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 3:54 AM EST - 3 months ago

West Pharmaceutical: Back To Growth

Nov 29, 2025, 8:02 AM EST - 3 months ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR

Nov 20, 2025, 2:43 PM EST - 3 months ago

West Pharmaceutical Services, Inc. (WST) Presents at Stephens Annual Investment Conference 2025 Transcript

Nov 18, 2025, 7:18 AM EST - 3 months ago

West Pharmaceutical Services, Inc. (WST) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 11:24 AM EST - 3 months ago

These stocks have been hit hard in 2025 but could surge by as much as 57% from here

ADBE ALGN BLDR CARR CMG CPRT CRM

Nov 11, 2025, 12:21 PM EST - 3 months ago

West Pharmaceutical Services, Inc. (WST) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 6, 2025, 8:10 AM EST - 3 months ago

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

AMZN BSX DKS INSM LHX SPOT TEAM

Oct 27, 2025, 6:00 AM EDT - 4 months ago

West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery

Oct 24, 2025, 6:00 AM EDT - 4 months ago

West to Participate in Upcoming Investor Conferences

Oct 23, 2025, 3:07 PM EDT - 4 months ago

West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 12:16 PM EDT - 4 months ago

West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand

Oct 23, 2025, 6:52 AM EDT - 4 months ago

West Pharma boosts annual profit forecast on strong demand for its drug components

Oct 23, 2025, 6:00 AM EDT - 4 months ago

West Reports Third-Quarter 2025 Results

Oct 21, 2025, 5:57 AM EDT - 4 months ago

West Pharmaceutical Services: HVP Moat Cum GLP-1 And Biologics Tailwinds Reinforce Upward Momentum

Oct 9, 2025, 6:00 AM EDT - 4 months ago

West to Host Third-Quarter 2025 Conference Call

Oct 3, 2025, 10:46 AM EDT - 5 months ago

Top 50 High-Quality Dividend Growth Stocks For October 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Oct 1, 2025, 10:58 PM EDT - 5 months ago

Top 15 High-Growth Dividend Stocks For October 2025

ACN DPZ EOG FDX INTU MSCI NDSN

Sep 24, 2025, 3:27 PM EDT - 5 months ago

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 6, 2025, 12:18 PM EDT - 6 months ago

Top 50 High-Quality Dividend Stocks For September 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Sep 3, 2025, 5:11 PM EDT - 6 months ago

West Pharmaceutical Services, Inc. (WST) Presents At Wells Fargo 2025 Healthcare Conference (Transcript)

Aug 27, 2025, 2:09 PM EDT - 6 months ago

Best Dividend Aristocrats For September 2025

ABBV ABT ADM ADP AFL ALB AMCR

Aug 21, 2025, 6:00 AM EDT - 6 months ago

West to Participate in Upcoming Investor Conferences in September 2025

Aug 6, 2025, 11:50 AM EDT - 7 months ago

Top 50 High-Quality Dividend Stocks For August 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Jul 30, 2025, 12:20 PM EDT - 7 months ago

West Pharmaceutical: Q2 Earnings Suggest Recovery

Jul 27, 2025, 1:52 AM EDT - 7 months ago

West Pharmaceutical Services: Low Debt, High Profit, And A Waning Destocking Problem

Jul 24, 2025, 1:58 PM EDT - 7 months ago

West Pharmaceutical Services, Inc. (WST) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 10:38 AM EDT - 7 months ago

West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars

Jul 24, 2025, 8:02 AM EDT - 7 months ago

West Pharma raises annual profit forecast on strong demand for its drug components

Jul 24, 2025, 6:00 AM EDT - 7 months ago

West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance

Jul 21, 2025, 6:00 AM EDT - 7 months ago

West Welcomes Robert McMahon as Incoming Chief Financial Officer

Jul 8, 2025, 6:00 AM EDT - 8 months ago

West to Host Second-Quarter 2025 Conference Call

Estimize Feb. 23 at 12:00 PM

Wall St is expecting 1.68 EPS for $WST Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_cont

0 · Reply

FadeLars Feb. 20 at 4:33 PM

$WST West Pharmaceutical supplies packaging for injectable drugs. Demand is stable and high margin. Growth tracks biologics adoption.

0 · Reply

deankell Feb. 18 at 1:37 AM

$WST West Pharmaceutical (WST) declares $0.22/share quarterly dividend, in line with previous. Forward yield 0.36% Payable May 6; for shareholders of record April 29; ex-div April 29.

0 · Reply

deankell Feb. 18 at 1:28 AM

0 · Reply

d_risk Feb. 17 at 10:04 PM

0 · Reply

ZacksResearch Feb. 12 at 7:04 PM

0 · Reply

ZacksResearch Feb. 12 at 6:04 PM

0 · Reply

Tokenist Feb. 12 at 1:32 PM

1 · Reply

StocktwitsEarnings Feb. 12 at 12:27 PM

0 · Reply

ZacksResearch Feb. 11 at 7:28 PM

0 · Reply

ZacksResearch Feb. 11 at 6:28 PM

Big day for med tech: $BAX, $WST & $DXCM 📊 Q4 earnings hit amid macro pressure, but steady revenue growth and AI-driven demand are key watchpoints. See what could move these stocks 👉 https://www.zacks.com/stock/news/2854637/medical-device-stocks-to-report-earnings-on-feb-12-bax-wst-dxcm?cid=sm-stocktwits-2-2854637-teaser-33201&ADID=SYND_STOCKTWITS_TWEET_2_2854637_TEASER_33201

0 · Reply

JackDarwin Feb. 9 at 10:11 AM

$WST Bullish Kicker Candlestick Pattern Formed

0 · Reply

OfficialStocktwitsUser Feb. 5 at 11:01 AM

$WST RSI: 29.13, MACD: -10.4975 Vol: 18.25, MA20: 253.10, MA50: 265.72 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Feb. 4 at 2:35 PM

$WST Share Price: $233.58 Contract Selected: Sep 18, 2026 $240 Calls Buy Zone: $25.21 – $31.15 Target Zone: $43.44 – $53.09 Potential Upside: 63% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

RunnerSignals Jan. 25 at 9:48 PM

$BHC $ORI $SHOP $NTNX $WST screaming oversold fear or opportunity? see which ones might bounce first https://stocksrunner.com/news/2026-01-25-identify-oversold-stocks-and-potential-reversals

0 · Reply

ZacksResearch Jan. 23 at 7:43 PM

West Pharma unveils a new syringe — small launch, big implications? 💉 $WST just debuted the Synchrony S1 prefillable syringe at Pharmapack 2026, designed to enhance support for biologics, vaccines, and home-care applications. Could this product deepen its positioning in high-growth therapies? Full details here 👉 https://www.zacks.com/stock/news/2822215/wst-launches-synchrony-s1-prefillable-syringe-at-pharmapack?cid=sm-stocktwits-2-2822215-teaser-30289&ADID=SYND_STOCKTWITS_TWEET_2_2822215_TEASER_30289

0 · Reply

AStrokeOfLuck Jan. 23 at 7:24 PM

$NVO $BDX $WST

1 · Reply

ZacksResearch Jan. 23 at 6:43 PM

$WST unveils Synchrony S1 syringe system, but shares dip 1.1%. Why? 🤔 🧪 Supports biologics & vaccines, aligning with combo products & home care trends 📉 Yet, stock down 11.2% in 6 months, lagging industry & S&P 500 growth Discover why this innovation could be a long-term driver for $WST 👉 https://www.zacks.com/stock/news/2822215/wst-launches-synchrony-s1-prefillable-syringe-at-pharmapack?cid=sm-stocktwits-2-2822215-body-30281&ADID=SYND_STOCKTWITS_TWEET_2_2822215_BODY_30281

0 · Reply

Arcides Jan. 16 at 9:26 PM

$WST breakdown with a lot of volume..next level of interest 239

0 · Reply

ZacksResearch Jan. 14 at 6:12 PM

$WST is heating up — but it’s not a one-way trade. 👀 Surging GLP-1 demand and HVP expansion are powering the bull case, even as pricing pressure, tariff risks, and contract manufacturing headwinds cloud the near-term outlook. ⚠️ Full bull vs. risk breakdown here 👉 https://www.zacks.com/stock/news/2817573/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2817573-teaser-28954&ADID=SYND_STOCKTWITS_TWEET_2_2817573_TEASER_28954

0 · Reply

ZacksResearch Jan. 14 at 5:12 PM

$WST up 21.1% in 6 months compared to industry's 0.8% return — what's driving the momentum? 🚀 🌟 Strong demand for GLP-1 therapies & Annex 1 regulatory upgrades 📈 13% organic growth in high-value product components 🔍 Zacks Rank #2 with a trailing 4-quarter earnings surprise of 15.52% Discover the full growth story here 👉 https://www.zacks.com/stock/news/2817573/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2817573-body-28955&ADID=SYND_STOCKTWITS_TWEET_2_2817573_BODY_28955

0 · Reply

ZacksResearch Dec. 11 at 2:31 PM

Is $WST poised for a comeback despite a rough start in 2023? 📉 The stock is down 18.5% YTD, but with a Zacks Rank #3 and a robust GLP-1 demand, WST is positioned for growth despite challenges like pricing headwinds and tariff risks. HVP components rose 13% organically, and free cash flow is up 54% YTD due to capital discipline and improved supply-chain efficiencies, indicating strong underlying momentum. 🚀 Explore the full analysis here 👉 https://www.zacks.com/stock/news/2802781/reasons-to-retain-west-pharmaceutical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2802781-body-24365&ADID=SYND_STOCKTWITS_TWEET_2_2802781_BODY_24365

0 · Reply

Market Cap	17.37B
Revenue (ttm)	3.07B
Net Income (ttm)	493.70M
EPS (ttm)	N/A
PE Ratio	33.45
Forward PE	30.39
Profit Margin	16.06%
Debt to Equity Ratio	0.06

Volume	856,000
Avg Vol	959,862
Day's Range	N/A - N/A
Shares Out	72.02M
Stochastic %K	42%
Beta	1.18
Analysts	Strong Sell
Price Target	$319.07